Peptilogics Reports Positive 180-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients with Periprosthetic Joint Infection (PJI)

September 19, 2023

Peptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients with Periprosthetic Joint Infection (PJI)

May 24, 2023

Peptilogics Completes Phase 1b Trial Enrollment and Will Present Interim Top-line Safety and Tolerability Data of PLG0206 in Patients Undergoing DAIR for the Treatment of Periprosthetic Joint Infection After a Total Knee Arthroplasty at ECCMID 2023

April 6, 2023

Peptilogics Hosting Panel Discussion with Leading Industry Experts on the High Unmet Medical Need and Opportunity in Periprosthetic Joint Infections (PJI)

February 21, 2023